Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Dna X (SONM) over the last 8 years, with Q3 2025 value amounting to $1.4 million.

  • Dna X's Change in Accured Expenses fell 8559.29% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.9 million, marking a year-over-year decrease of 12293.96%. This contributed to the annual value of $8.0 million for FY2024, which is 48787.66% up from last year.
  • Per Dna X's latest filing, its Change in Accured Expenses stood at $1.4 million for Q3 2025, which was down 8559.29% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Dna X's Change in Accured Expenses ranged from a high of $9.8 million in Q3 2024 and a low of -$2.9 million during Q1 2021
  • For the 5-year period, Dna X's Change in Accured Expenses averaged around $467578.9, with its median value being $315000.0 (2022).
  • Over the last 5 years, Dna X's Change in Accured Expenses had its largest YoY gain of 188641.98% in 2023, and its largest YoY loss of 77809.52% in 2023.
  • Quarter analysis of 5 years shows Dna X's Change in Accured Expenses stood at -$331000.0 in 2021, then surged by 124.47% to $81000.0 in 2022, then skyrocketed by 1886.42% to $1.6 million in 2023, then plummeted by 275.7% to -$2.8 million in 2024, then soared by 149.77% to $1.4 million in 2025.
  • Its Change in Accured Expenses stands at $1.4 million for Q3 2025, versus -$1.2 million for Q2 2025 and -$218000.0 for Q1 2025.